BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26739893)

  • 1. Repeated administration of low-dose cisplatin in mice induces fibrosis.
    Sharp CN; Doll MA; Dupre TV; Shah PP; Subathra M; Siow D; Arteel GE; Megyesi J; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2016 Mar; 310(6):F560-8. PubMed ID: 26739893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease.
    Sharp CN; Doll MA; Megyesi J; Oropilla GB; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2018 Jul; 315(1):F161-F172. PubMed ID: 29384415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity.
    Orwick A; Sears SM; Sharp CN; Doll MA; Shah PP; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2023 Mar; 324(3):F287-F300. PubMed ID: 36727944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
    Al Za'abi M; Al Salam S; Al Suleimani Y; Ashique M; Manoj P; Nemmar A; Ali BH
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):249-259. PubMed ID: 32936352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing better mouse models to study cisplatin-induced kidney injury.
    Sharp CN; Siskind LJ
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F835-F841. PubMed ID: 28724610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition.
    Katagiri D; Hamasaki Y; Doi K; Negishi K; Sugaya T; Nangaku M; Noiri E
    Kidney Int; 2016 Feb; 89(2):374-85. PubMed ID: 26535996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibitors of autophagy have opposite effects in acute and chronic cisplatin-induced kidney injury.
    Sears SM; Feng JL; Orwick A; Vega AA; Krueger AM; Shah PP; Doll MA; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2022 Sep; 323(3):F288-F298. PubMed ID: 35796459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.
    Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N
    Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suramin protects from cisplatin-induced acute kidney injury.
    Dupre TV; Doll MA; Shah PP; Sharp CN; Kiefer A; Scherzer MT; Saurabh K; Saforo D; Siow D; Casson L; Arteel GE; Jenson AB; Megyesi J; Schnellmann RG; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2016 Feb; 310(3):F248-58. PubMed ID: 26661653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury.
    Sears SM; Sharp CN; Krueger A; Oropilla GB; Saforo D; Doll MA; Megyesi J; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F674-F685. PubMed ID: 32830540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.
    Menshikh A; Scarfe L; Delgado R; Finney C; Zhu Y; Yang H; de Caestecker MP
    Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1383-F1397. PubMed ID: 31509009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate aging does not exacerbate cisplatin-induced kidney injury or fibrosis despite altered inflammatory cytokine expression and immune cell infiltration.
    Sharp CN; Doll M; Dupre TV; Beverly LJ; Siskind LJ
    Am J Physiol Renal Physiol; 2019 Jan; 316(1):F162-F172. PubMed ID: 30484347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury.
    Holditch SJ; Brown CN; Lombardi AM; Nguyen KN; Edelstein CL
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31226747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 T cell knockout does not protect against kidney injury and worsens cancer.
    Ravichandran K; Wang Q; Ozkok A; Jani A; Li H; He Z; Ljubanovic D; Weiser-Evans MC; Nemenoff RA; Edelstein CL
    J Mol Med (Berl); 2016 Apr; 94(4):443-55. PubMed ID: 26620676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human umbilical cord blood mononuclear cells protect against renal tubulointerstitial fibrosis in cisplatin-treated rats.
    Li XW; Feng LX; Zhu XJ; Liu Q; Wang HS; Wu X; Yan P; Duan XJ; Xiao YQ; Cheng W; Peng JC; Zhao F; Deng YH; Duan SB
    Biomed Pharmacother; 2020 Jan; 121():109662. PubMed ID: 31810124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells.
    Fu Y; Cai J; Li F; Liu Z; Shu S; Wang Y; Liu Y; Tang C; Dong Z
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1582-F1592. PubMed ID: 31532246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Therapeutic Targets for Cisplatin-Induced Kidney Injury: Lessons from Other Models of AKI and Fibrosis.
    Sears SM; Siskind LJ
    J Am Soc Nephrol; 2021 Jul; 32(7):1559-1567. PubMed ID: 34049962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.
    Landau SI; Guo X; Velazquez H; Torres R; Olson E; Garcia-Milian R; Moeckel GW; Desir GV; Safirstein R
    Kidney Int; 2019 Apr; 95(4):797-814. PubMed ID: 30904067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.
    Solanki MH; Chatterjee PK; Xue X; Gupta M; Rosales I; Yeboah MM; Kohn N; Metz CN
    Am J Physiol Renal Physiol; 2015 Jul; 309(1):F35-47. PubMed ID: 25947343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
    Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
    Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.